Wednesday, 22 February 2017

Exercise a powerful ally for breast cancer survivors

New research from Canada indicates that exercise more than any other healthy habit lowers a breast cancer survivors chance of dying.  According to author Dr. Ellen Warner, medical oncology at Sunnybrook Odette Cancer Centre in Ontario, of all of the lifestyle changes patients made in reducing the risk of cancer recurrence, "exercise came out on top, reducing the risk of breast cancer death by about 40%."

To read more about this study, click here.

Tuesday, 14 February 2017

Long-term adjuvant Tamoxifen therapy and decreases in contralateral breast cancer

Tamoxifen revolutionized personalized medicine as the first targeted therapy proven to save lives in cancer. The paradigm change proposed to block the breast tumor estrogen receptor (ER), apply long-term adjuvant therapy to block estrogen-stimulated recurrences, and apply the potential of tamoxifen to prevent breast cancer. These recommendations have been put into clinical practice for three decades. Please read the latest JAMA editorial on this therapy.

Study mentioned:
Abderrahman B, Jordan VC. Long-term Adjuvant Tamoxifen Therapy and Decreases in Contralateral Breast Cancer . JAMA Oncol. 2017;3(2):163-164. doi:10.1001/jamaoncol.2016.3324

The nuclear transport receptor Importin-11 is a tumor suppressor that maintains PTEN protein

Rockefeller University investigators identify a key anti-cancer protein - the study was recently published. Please read more from the Journal of Cell Biology here.

Friday, 10 February 2017

Cancer incidence and mortality rates in Alberta on downward trend

The newly released Report on Cancer Statistics in Alberta indicates that incidence rates of cancer have declined by 0.6% annually between 2001-2014, with a 2.1% decrease per year in mortality rates during that same time period.  The Screening for Life Program emphasizes the importance of early detection and screening on a patient's rate of survival.  According to Dr. Huiming Yang, Medical Director, Screening, Population, Public, and Indigenous Health, "we want Albertans to know what screening options are available to them and we need everyone to take personal responsibility for their health and well-being by asking their doctor about what cancer screening programs are right for them."

To read more about this report, click here.

Thursday, 2 February 2017

Breath test may be able to detect stomach cancers earlier

Research recently presented at the European Cancer Congress (ECC) indicates that a breath test may be able to detect earlier incidents of stomach and esophageal cancers.  According to study author Dr. Sheraz Markar from Imperial College in London, A breath test could be used as a noninvasive, first-line test to reduce the number of unnecessary endoscopies."  Measuring 5 chemicals in breath, this test, conducted on more than 300 patients has been found to be 85% accurate.

To read more about this study, click here.

Thursday, 26 January 2017

HPV vaccine does not eliminate need for Pap test

With January being designated as Cervical Health Awareness Month, oncologists are reminding patients about the importance and need for women of all ages to undergo Pap test screening.  According to Dr. Jayanthi Lea, from UT Southwestern Medical Center in Dallas, "the [HPV] vaccine reduces the risk of cancer, but has not yet been shown to eliminate the need for screening."

Click here to read more.

Wednesday, 18 January 2017

Even small amount of daily activity can boost colon cancer survival

A new U.S. study conducted on 1,200 colon cancer patients indicated a 19% decrease in early risk of death for those exercising 30 minutes or more on a daily basis. Further, individuals who exercised at least 5 hours per week saw their survival rate rise to 25%.  According to Dr. Andrew Chan, associate professor of medicine at Harvard Medical School, these findings do support the notion that "patients who have cancer and who are physically active...have a better prognosis."

To read more about this study, click here.

Friday, 13 January 2017

Chemo Brain may last for several months after breast cancer treatment

A new study conducted in the United States, considered to be the largest of its kind to date, explored explored the effects of memory and attention issues affecting breast cancer survivors after undergoing chemotherapy treatment.  According to study author Michelle Janelsins, assistant professor o surgery, radiation oncology and neuroscience at the University of Rochester Medical Center and the Wilmot Cancer Institute in New York, "a month after chemo ended, 45% of patients reported a significant decline in so-called cognitive abilities", an effect that continued to linger 6 months later where "36% of patients still felt their mental ability had declined."

To read more about this study, click here.

Friday, 6 January 2017

Drug for advanced bone cancer may require less frequent dosing

Researchers at the Helen F. Graham Cancer Center & Research Institute in Newark, Delaware have determined that use of Zometa, a drug used to treat bone cancer, reduces side effects in patients and increases cost savings wen administered every 3 months instead of monthly.  This change in dosage has not resulted in increased risk of bone problems over a 2-year period.  The study, conducted on more than 1800 patients with breast cancer, prostate cancer, or multiple myeloma indicated bone problems in 30% of patients who received the drug monthly compared to 29% who were administered the drug every 3 months.

To read more about this study, click here.

Tuesday, 3 January 2017

New targeted therapies show promise for treating advanced GIST

Two early-phase clinical trials testing new targeted therapies for advanced gastrointestinal stromal tumors (GIST) have produced promising preliminary results. Although the findings are preliminary, Lee Helman, M.D., of NCI's Center for Cancer Research, said the drugs show substantial promise as a treatment for patients with GIST whose tumors stop responding to standard therapies.

The trial results were presented earlier this month at the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics ConferenceExit Disclaimer in Munich.

Read more here.